First‐trimester exposure to tofacitinib in ulcerative colitis: A case report of a healthy newborn and literature review

Abstract

Key Clinical Message Tofacitinib is contraindicated in pregnancy. We present a patient with ulcerative colitis on tofacitinib who had an unplanned pregnancy. Tofacitinib was ceased, switched to vedolizumab, and she gave birth to a healthy newborn at term. Case reports of reassuring outcomes provide real‐world data that assists decision‐making for future patients.

Keywords

• case report
• inflammatory bowel diseases
• Janus kinase inhibitors
• pregnancy
• tofacitinib
• ulcerative colitis